AI VIVO LTD

AI VIVO’s mission is to transform drug discovery and pharmacology by bridging the gap between complex biological systems and computational modelling, helping pharmaceutical and biotech companies understand disease dynamics more effectively and accelerate the development of new medicines.

AI VIVO is an early‑stage biotechnology company pioneering AI‑driven drug discovery with a focus on organism‑level biology modelling. The company develops advanced artificial intelligence systems that generate multi‑modal omics data to construct detailed biological models, known as OrganoMaps, that link disease biology with treatment interventions at the organ and organism scale. 

The core of AI VIVO’s technology is the Organome Platform—a generative AI system capable of simulating biological processes from molecular targets up through tissue, organ, and whole‑organism levels to accelerate discovery and development of targeted medicines. This approach aims to address limitations in conventional drug development, which often relies on cell‑based or animal models that fail to capture complexity at higher biological scales.

• Immunology/inflammation
• Infectious diseases